Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.
Publication
, Journal Article
Beckabir, W; Zhou, M; Lee, JS; Vensko, SP; Woodcock, MG; Wang, H-H; Wobker, SE; Atassi, G; Wilkinson, AD; Fowler, K; Flick, LM; Damrauer, JS ...
Published in: Nat Commun
May 24, 2024
Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC). Immune checkpoint inhibition (ICI) alone, and ICI in combination with chemotherapy, have demonstrated promising pathologic response (
Duke Scholars
Published In
Nat Commun
DOI
EISSN
2041-1723
Publication Date
May 24, 2024
Volume
15
Issue
1
Start / End Page
4448
Location
England
Related Subject Headings
- Urinary Bladder Neoplasms
- Treatment Outcome
- Neoplasm Invasiveness
- Neoadjuvant Therapy
- Middle Aged
- Male
- Interleukin-9
- Immunotherapy
- Immune Checkpoint Inhibitors
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Beckabir, W., Zhou, M., Lee, J. S., Vensko, S. P., Woodcock, M. G., Wang, H.-H., … Vincent, B. G. (2024). Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer. Nat Commun, 15(1), 4448. https://doi.org/10.1038/s41467-024-48480-1
Beckabir, Wolfgang, Mi Zhou, Jin Seok Lee, Steven P. Vensko, Mark G. Woodcock, Hsing-Hui Wang, Sara E. Wobker, et al. “Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.” Nat Commun 15, no. 1 (May 24, 2024): 4448. https://doi.org/10.1038/s41467-024-48480-1.
Beckabir W, Zhou M, Lee JS, Vensko SP, Woodcock MG, Wang H-H, et al. Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer. Nat Commun. 2024 May 24;15(1):4448.
Beckabir, Wolfgang, et al. “Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.” Nat Commun, vol. 15, no. 1, May 2024, p. 4448. Pubmed, doi:10.1038/s41467-024-48480-1.
Beckabir W, Zhou M, Lee JS, Vensko SP, Woodcock MG, Wang H-H, Wobker SE, Atassi G, Wilkinson AD, Fowler K, Flick LM, Damrauer JS, Harrison MR, McKinnon KP, Rose TL, Milowsky MI, Serody JS, Kim WY, Vincent BG. Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer. Nat Commun. 2024 May 24;15(1):4448.
Published In
Nat Commun
DOI
EISSN
2041-1723
Publication Date
May 24, 2024
Volume
15
Issue
1
Start / End Page
4448
Location
England
Related Subject Headings
- Urinary Bladder Neoplasms
- Treatment Outcome
- Neoplasm Invasiveness
- Neoadjuvant Therapy
- Middle Aged
- Male
- Interleukin-9
- Immunotherapy
- Immune Checkpoint Inhibitors
- Humans